Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SPEX.SW
- Price
- 4298.50
- Stock movement down
- -0.03 (-75.00%)
- Company name
- Spexis AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 676.64K
- Ent value
- 14.72M
- Price/Sales
- -
- Price/Book
- 0.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -93.01%
- 3 year return
- -79.95%
- 5 year return
- -71.40%
- 10 year return
- -
Last updated: 2025-03-14
DIVIDENDS
SPEX.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.30 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 67.66M |
| EPS (TTM) | - |
| FCF per share (TTM) | -0.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 0.00 |
| Net income (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 444.83K |
| Net receivables | 0.00 |
| Total current assets | 3.29M |
| Goodwill | 7.69M |
| Intangible assets | 5.02M |
| Property, plant and equipment | 1.19M |
| Total assets | 16.78M |
| Accounts payable | 3.28M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 8.71M |
| Total liabilities | 14.49M |
| Shareholder's equity | 2.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.49M |
| Capital expenditures (TTM) | 8.46K |
| Free cash flow (TTM) | -5.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | -97.65% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.05 |
| Daily high | 0.06 |
| Daily low | 0.01 |
| Daily Volume | 0K |
| All-time high | 4564.00 |
| 1y analyst estimate | 1.80 |
| Beta | 0.26 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SPEX.SW | S&P500 | |
| Current price drop from All-time high | -5.82% | -12.44% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 13 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -82.50% | -11.07% |
| Avg time to new high | 1719 days | 12 days |
| Max time to new high | 1718 days | 1805 days |
COMPANY DETAILS
Marketcap
676.64K
Marketcap category
Small-cap
Description
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Employees
50
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found